Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study will examine multiple carefully selected clinical and biological markers, using
both existing state-of-the-art technologies as well as pioneering, innovative approaches. The
study is designed to identify moderators and mediators of treatment response for depression
in order to specify a biosignature of treatment response for depression. Evaluation of the
usefulness of these markers in a carefully conducted clinical trial comparing an
antidepressant to placebo will assist in developing a Depression Treatment Response Index
(DTRI) to help clinicians match treatments to patients with MDD, resulting in timely
selection of treatments best suited for individual patients and thus approaching personalized
treatment. The resulting index provides a truly novel means of synthesizing the contribution
of key clinical and biological parameters in an easy to use tool for clinical care.